Presenter: Joseph O’Donoghue, Ph.D. | Attending Physicist, Memorial Sloan-Kettering Cancer Center
Radiopharmaceutical therapies exploit the tumor targeting ability of small molecules, peptides, or antibodies to treat solid cancers with cytotoxic radiation while limiting damage to normal tissues.
During this webinar, the presenter will discuss:
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
Attending Physicist, Memorial Sloan-Kettering Cancer Center
Dr. O’Donoghue is a medical physicist with a long-standing interest in the imaging and treatment of malignant disease by molecular-targeted radionuclides. Dr. O’Donoghue’s work includes radiation dosimetry, radiobiological modeling, experimental and clinical nuclear imaging, kinetic analysis and tumor response assessment for radiolabeled antibodies and small molecules. In the lab he has investigated the application of ex-vivo analysis featuring digital autoradiography and immunohistochemistry to examine the microdistribution of targeted radionuclides in patient tumors.
